Resveratrol prevents p53 aggregation in vitro and in breast cancer cells

One potential target for cancer therapeutics is the tumor suppressor p53, which is mutated in more than 50% of malignant tumors. Loss of function (LoF), dominant negative (DN) and gain of function (GoF) mutations in p53 are associated with amyloid aggregation. We tested the potential of resveratrol,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Ferraz da Costa, Danielly C., Campos, Nathali P.C., Santos, Ronimara A., Guedes-da-Silva, Francisca Hildemagna, Martins-Dinis, Mafalda Maria D.C., Zanphorlin, Letícia, Ramos, Carlos, Rangel, Luciana P., Silva, Jerson L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6044377/
https://ncbi.nlm.nih.gov/pubmed/30018739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25631
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi